$MRVI Income Statement | Understand Stock

$MRVI

$8.50 +$0.24 (2.91%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
Cost of revenue
Gross profit
Operating expenses:
Selling, general and administrative
Research and development
Change in estimated fair value of contingent consideration
Goodwill impairment
Impairment of goodwill and long-lived assets
Restructuring
Gain on sale of business
Gain on sale and leaseback transaction
Total operating expenses

Loss from operations
Other income (expense):
Interest expense
Interest income
Loss on extinguishment of debt
Change in payable to related parties pursuant to the Tax Receivable Agreement
Other expense
(Loss) income before income taxes
Income tax (benefit) expense
Net loss attributable to non-controlling interests
Net loss attributable to Maravai LifeSciences Holdings, Inc.
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc. - basic (in usd per share)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc. - diluted (in usd per share)
Weighted average Class A common shares outstanding—basic (in shares)
Weighted average Class A common shares outstanding - diluted (in shares)

Comments